EUCTR2007-001068-55-GB进行中（未招募）不适用
A Phase II, Open Label Pilot Study to Evaluate the Safety and Efficacy of A Bioresorbable Subcutaneous Implant of CUV1647 in Patients with Solar Urticaria (SU) - Phase II SU Pilot Study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Male or female subjects with a diagnosis of solar urticaria (confirmed by phototesting) of sufficient severity that they have requested treatment to alleviate symptoms.
- •-React to provocation with a light source
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •-Current Bowen’s disease, basal cell carcinoma, squamous cell carcinoma, or other malignant or premalignant skin lesions.
- •--Female who is pregnant (confirmed by positive serum ß-HCG pregnancy test prior to baseline) or lactating.
- •-Females of child-bearing potential (pre-menopausal, not surgically sterile) not using adequate contraceptive measures (i.e. oral contraceptives, diaphragm plus spermicide, intrauterine device).
- •-Any factors that may affect skin reflectance measurements.
研究者
相似试验
已完成
2 期
Study drug ELX-02 for patients with Alport syndromeGenetic DiseasesOther specified congenital malformation syndromes, not elsewhere classifiedAlport syndromeISRCTN12014920Eloxx Pharmaceuticals (United States)3
进行中（未招募）
不适用
A Phase II, Randomised, Open Label Pilot Study to Evaluate the Efficacy and Safety of Two Dosage Regimens of Subcutaneous Bioresorbable Afamelanotide Implants in Patients with Mild to Moderate Acne Vulgaris. - Phase II Acne Vulgaris Pilot StudyAcne vulgarisMedDRA version: 12.1Level: LLTClassification code 10000519Term: Acne vulgarisEUCTR2009-018024-15-DEClinuvel Pharmaceuticals Limited10
进行中（未招募）
1 期
An Open-Label, Phase 2, Pilot Study Investigating the Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics of Oral Treatment with the BTK Inhibitor PRN1008 in Patients with Newly Diagnosed or Relapsing Pemphigus VulgarisPemphigus: Pemphigus VulgarisMedDRA version: 20.0Level: LLTClassification code 10052802Term: Pemphigus vulgarisSystem Organ Class: 100000004858EUCTR2015-003564-37-HRPrincipia Biopharma Australia Pty Ltd42
进行中（未招募）
1 期
A Pilot Study Investigating the Safety, Clinical Activity, Drug Levels, and Effects on PRN 1008 in Patients with Newly Diagnosed or Relapsing Pemphigus VulgarisPemphigus: Pemphigus VulgarisMedDRA version: 18.1Level: LLTClassification code 10052802Term: Pemphigus vulgarisSystem Organ Class: 100000004858EUCTR2015-003564-37-GRPrincipia Biopharma Australia Pty Ltd25
进行中（未招募）
1 期
A dose escalation trial to assess the safety and tolerability of multiple doses of the LAVA-051 antibody in patients with chronic lymphocytic leukemia, multiple myeloma or acute myeloid leukemiaCD1d-positive relapsed/refractory chronic lymphocytic leukemia (CLL), multiple myeloma (MM), or acute myeloid leukemia (AML)EUCTR2020-004583-26-ESAVA Therapeutics B.V.102